Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Faivre‐Finn, Corinne; Snee, M.; Ashcroft, Linda; Appel, W.; Barlési, Fabrice; Bhatnagar, Adityanarayan; Bezjak, Andrea; Cardenal, Felipe; Fournel, P.; Harden, Susan; Le Péchoux, C.; McMenemin, R.; Mohammed, Nazia; O’Brien, Mary; Pantarotto, Jason; Surmont, Veerle; P. van Meerbeeck, Jan; J. Woll, Penella; Lorigan, Paul; Blackhall, Fiona

doi:10.1016/s1470-2045(17)30318-2

Public

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Published in The Lancet Oncology • Jun 20, 2017

Authors:

Corinne Faivre‐Finn

M. Snee

Linda Ashcroft

Abstract

BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cance...

Subject

Medicine

Chemoradiotherapy

Regimen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!